T-cell receptor

Overview

The T-cell receptor (TCR) is a membrane-bound antigen receptor expressed by T lymphocytes and is central to adaptive immunity. It recognizes antigenic Peptides presented by major histocompatibility complex molecules, enabling T cells to detect infected, malignant, or otherwise altered cells. In this way, TCR specificity underlies T-cell activation, tolerance, effector function, and the distinction between productive immune responses and anergic or nonresponsive states.

Structurally and functionally, TCRs are most often discussed in the context of their variable regions, especially the complementarity-determining region 3 (CDR3), which contributes strongly to antigen specificity. Because TCR recognition is HLA-restricted and depends on peptide-MHC affinity and avidity, the receptor is a major focus in cancer immunotherapy, infectious disease research, and immune engineering. Recent work has also expanded TCR research into single-cell and spatial multi-omics, computational binding prediction, and engineered cell therapies, including T-cell receptor gene transfer alongside chimeric antigen receptor approaches.

Focus of Latest Publications

Recent publications have used the T-cell receptor as both a biological readout and an engineering target across immunology and cancer therapy.

Several studies focused on TCR–peptide-MHC recognition as a basis for immune activation. A Science Advances study on ready-to-load MHC-I nanoparticles emphasized that the affinity and avidity of interactions between peptide-MHC molecules and cognate T-cell receptors are fundamental determinants of whether T cells become activated or anergic. This places TCR binding at the center of high-throughput T cell screening systems designed to probe antigen specificity. In a related computational direction, a Cell Reports Methods paper introduced a lightweight TcrLM model to predict TCR and epitope binding specificity, reflecting the growing use of machine learning to infer receptor–antigen pairing from sequence data. The study framed immune responses as dependent on specific interactions between TCRs and Peptides presented by antigen-presenting cells.

TCR profiling and clonotype detection were also major themes. A Genome Medicine study presented circVDJ-seq, a simplified and cost-efficient method for TCR profiling from 3'-directed workflows such as single-cell RNA sequencing, single-nucleus RNA sequencing, ATAC + RNA multi-omics, and spatial transcriptomics. This work highlights the use of TCR sequence information as a clonotypic marker in single-cell and spatial immune profiling. Similarly, high-resolution sequencing technologies and immunogenomic analysis were used to support TCR discovery and repertoire analysis across complex samples.

In cancer immunotherapy, TCRs were repeatedly discussed as a mechanism for tumor antigen recognition. A Blood review on neoantigen-specific T cells described how endogenous T-cell receptors recognize tumor-derived Peptides in an HLA-restricted context, distinguishing TCR-based therapies from chimeric antigen receptor T cell therapy. A Clinical Cancer Research article on checkpoint resistance described redirection of effector cells by imposing novel tumor specificity via engineered T-cell receptors, chimeric antigen receptors, and CD3/TCR engagers. Another Science Advances study showed that engaging the endogenous TCR of CAR T cells with an oncolytic virus enhanced CAR T cell functionality, durability, and therapy, indicating that endogenous TCR signaling can modulate engineered cell performance.

TCR engineering was also a prominent translational theme. A Biochemical and Biophysical Research Communications study reported targeted introduction of T-cell receptor genes at the TRAC locus in cytotoxic T lymphocytes regenerated from human iPSCs by genome editing, building on prior demonstrations that tumor antigen-specific TCR genes delivered by retroviral or lentiviral vectors can confer antitumor activity. A Nature study on in vivo site-specific engineering described reprogramming T cells to express chimeric antigen receptors or T-cell receptors as a strategy that has transformed cancer treatment and is being explored for autoimmune and infectious diseases. These studies place TCRs within next-generation genome editing and off-the-shelf platforms for cell therapy.

Other recent work expanded the antigenic scope of TCR biology. An ACS Nano study used a nanovial-based functional screening platform to discover metabolite-reactive TCRs from unconventional T cells in human blood, showing that TCR specificity can extend beyond conventional peptide antigens. A review of NY-ESO-1 in triple-negative breast cancer discussed the structural basis of NY-ESO-1 recognition by T-cell receptors and antibodies, along with epigenetic regulation via DNA methylation or histone modifications and expression patterns relevant to clinical disease. Across these studies, TCRs were linked to cancer immunotherapy, neoantigen-specific T-cell immunotherapies, melanoma cohort analyses, neuroblastomas, and broader precision TCR discovery efforts.

The publication contexts also indicate use of TCRs in disease-specific immune profiling, including Coronavirus Disease of 2019 and Pediatric Pneumonia, where peptide sets such as a COVID-19 peptide set and HLA allotypes may be used to study antigen-specific responses. Related entities such as CD8+ S100B+ T cells, IFNG, checkpoint inhibitor, and DNA methylation provide additional context for how TCR-driven immunity is integrated into tumor and inflammatory biology.

Key Publications

• Jun A Deep Learning-Driven Framework Integrating Organoid-Based Functional Validation Identifies Universal Neoantigens from Recurrent Glioma Mutations. (Cancer research, 2026, PMID 41886621): "TCRscore, based on publicly available datasets by integrating human leukocyte antigen binding and T-cell receptor (TCR) recognition features."
• Jun Ready-to-load MHC-I nanoparticles for high-throughput T cell screening studies. (Science advances, 2026, PMID 42284409): "The affinity and avidity of interactions between peptide-MHC molecules and their cognate T cell receptors (TCRs) are fundamental parameters that contribute to the induction of activated or anergic T cell states."
• Jun circVDJ-seq for T cell clonotype detection in single-cell and spatial multi-omics. (Genome medicine, 2026, PMID 42271498): "Here, we introduce circVDJ-seq for simplified and cost-efficient T cell receptor (TCR) profiling from 3'-directed workflows like single-cell or single-nucleus RNA sequencing, ATAC + RNA multi-omics, and spatial transcriptomics."
• Jun Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity. (Science advances, 2026, PMID 42247513): "Here, we show that engaging the CAR T cell endogenous T cell receptor (TCR) using an oncolytic virus enhances CAR T cell functionality, durability, and therapy."
• May A lightweight TcrLM model predicts T cell receptor and epitope binding specificity. (Cell reports methods, 2026, PMID 41923632): "Immune responses depend on specific interactions between T cell receptors (TCRs) and peptides presented by antigen-presenting cells (APCs)."
• May Targeted introduction of T cell receptor genes at the TRAC locus in cytotoxic T lymphocytes regenerated from human iPSCs by genome editing. (Biochemical and biophysical research communications, 2026, PMID 41856057): "Indeed, we previously demonstrated that introducing tumor antigen-specific TCR genes into iPSC-derived CTLs using retroviral or lentiviral vectors confers effective antitumor activity."
• Apr Universal Nanovial Screening Enables Functional Discovery of Metabolite-Reactive T-Cell Receptors for Cancer Therapy. (ACS nano, 2026, PMID 41990155): "Here, we develop a nanovial-based functional screening platform for the high-throughput discovery of TCRs from unconventional T cells present in human blood."
• Apr Harnessing Neoantigen-specific T Cells for Precision Immunotherapy in Hematologic Malignancies. (Blood, 2026, PMID 42008381): "Neoantigen-specific therapies that exploit the ability of endogenous T-cell receptors (TCRs) to recognize tumor-derived peptides in a human leukocyte antigen (HLA)-restricted context differ mechanistically from modalities employing chimeric antigen receptor (CAR) T cells."
• Apr Cell Therapies and Bispecific Engagers: Redefining Strategies against Checkpoint Resistance. (Clinical cancer research : an official journal of the American Association for Cancer Research, 2026, PMID 41661081): "redirection of effector cells by imposing novel tumor specificity via engineered T-cell receptors (TCR), chimeric antigen receptors (CAR), and CD3/TCR engagers"
• Apr NY-ESO-1 in Triple-Negative Breast Cancer: Systematic Review, Meta-Analysis, and Immunotherapeutic Implications. (International immunopharmacology, 2026, PMID 41846058): "This review provides comprehensive discussion of NY-ESO-1 including its structural basis of NY-ESO-1 recognition by T cell receptors (TCRs) and antibodies, epigenetic regulation via DNA methylation or histone modifications, and expression patterns or clinical relevance in TNBC."